THE WOODLANDS, Texas, Dec. 2, 2013 /PRNewswire/ -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) will hold its R&D Day on Thursday, December 5, 2013 from 9:00 a.m. to 12:00 p.m. Eastern Time at the Yale Club, 50 Vanderbilt Ave., in New York City. Members of Lexicon's senior management team will provide in-depth reviews of the company's drug development programs. The agenda will include a presentation by guest speaker Jake Kushner, M.D., Section Head, Pediatric Diabetes and Endocrinology, Baylor College of Medicine, titled "Type 1 Diabetes, a Clinical Area of Tremendous Unmet Need". To attend in person, please RSVP to firstname.lastname@example.org or 281-863-3264. A live webcast of the event may be accessed on Lexicon's corporate website at www.lexpharma.com. An archived version of the webcast will be available for 10 days after the event on the company's website. About LexiconLexicon is a biopharmaceutical company focused on discovering breakthrough treatments for human disease. Lexicon currently has multiple programs in clinical development for diabetes, irritable bowel syndrome, carcinoid syndrome and other indications, all of which were discovered by Lexicon's research team. Lexicon has used its proprietary gene knockout technology to identify more than 100 promising drug targets. Lexicon has focused drug discovery efforts on these biologically-validated targets to create its extensive pipeline of clinical and preclinical programs. For additional information about Lexicon and its programs, please visit www.lexpharma.com. Safe Harbor StatementThis press release contains "forward-looking statements," including statements relating to Lexicon's growth and future operating results, discovery and development of products, strategic alliances and intellectual property, as well as other matters that are not historical facts or information. All forward-looking statements are based on management's current assumptions and expectations and involve risks, uncertainties and other important factors, specifically including those relating to Lexicon's ability to successfully conduct preclinical and clinical development of its potential drug candidates, advance additional candidates into preclinical and clinical development, obtain necessary regulatory approvals, achieve its operational objectives, obtain patent protection for its discoveries and establish strategic alliances, as well as additional factors relating to manufacturing, intellectual property rights, and the therapeutic or commercial value of its drug candidates, that may cause Lexicon's actual results to be materially different from any future results expressed or implied by such forward-looking statements. Information identifying such important factors is contained under "Risk Factors" in Lexicon's annual report on Form 10-K for the year ended December 31, 2012, as filed with the Securities and Exchange Commission. Lexicon undertakes no obligation to update or revise any such forward-looking statements, whether as a result of new information, future events or otherwise.